Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- 25 June 2018
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 29 (8), 1861-1868
- https://doi.org/10.1093/annonc/mdy226
Abstract
Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th Edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant targeted or immune therapy. Patterns of pathologic response provided context to inform these guidelines. Based on our collective experience and guided by efforts in well-established neoadjuvant settings like breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant targeted and immune checkpoint therapy is described and illustrated. Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.Keywords
Funding Information
- National Cancer Institute (R01 CA142779)
- Australian National Health and Medical Research Council Practitioner Fellowship
- NIH (T32 CA193145)
This publication has 25 references indexed in Scilit:
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysisEuropean Urology, 2014
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointThe Lancet Oncology, 2014
- Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapyAnnals of Oncology, 2013
- A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsThe Lancet Oncology, 2012
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- The current landscape of locally advanced rectal cancerNature Reviews Clinical Oncology, 2011
- Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient OutcomeJournal of Clinical Oncology, 2005
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJNCI Journal of the National Cancer Institute, 2005